Sign In
Buy HALO
$69.82
+3.54 (+5.34%)
At Close: Jun 03, 2026
5 Reasons Why You Should Add Halozyme (HALO) to Your Portfolio
11:17am, Thursday, 19'th May 2022
We provide five reasons, which make Halozyme (HALO) a good investment option in 2022.
Community Health (CYH) Boosts Obstetrics Care With Technology
02:44pm, Tuesday, 17'th May 2022 Zacks Investment Research
Community Health (CYH) employs PeriGen's technology to bring about enhanced obstetrics services and assure the safety of mothers as well as babies in the labor and delivery procedures.
Is Galapagos (GLPG) Outperforming Other Medical Stocks This Year?
01:40pm, Monday, 16'th May 2022 Zacks Investment Research
Here is how Galapagos NV (GLPG) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
Halozyme (HALO) Q1 Earnings Miss, Royalties Aid Y/Y Revenues
01:36pm, Wednesday, 11'th May 2022 Zacks Investment Research
Halozyme (HALO) first-quarter earnings and sales miss estimates. Strong demand for the partnered drug, subcutaneous Darzalex, boosts the top line.
Halozyme (HALO) Q1 Earnings Miss, Royalties Aid Y/Y Revenues
11:17am, Wednesday, 11'th May 2022
Halozyme (HALO) first-quarter earnings and sales miss estimates. Strong demand for the partnered drug, subcutaneous Darzalex, boosts the top line.
Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q1 2022 Results - Earnings Call Transcript
10:14pm, Tuesday, 10'th May 2022
Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Helen Torley - President & Chief Executive Officer Nicole LaBrosse - Chief Fina
Halozyme Therapeutics (HALO) Q1 Earnings and Revenues Miss Estimates
09:25pm, Tuesday, 10'th May 2022 Zacks Investment Research
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -2.08% and 7.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Halozyme Therapeutics (HALO) Q1 Earnings and Revenues Miss Estimates
06:49pm, Tuesday, 10'th May 2022
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -2.08% and 7.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Heska (HSKA) Misses Q1 Earnings and Revenue Estimates
01:35pm, Monday, 09'th May 2022 Zacks Investment Research
Heska (HSKA) delivered earnings and revenue surprises of -34.15% and 3.44%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Lags Revenue Estimates
12:45pm, Wednesday, 04'th May 2022 Zacks Investment Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -4% and 10.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Halozyme To Host First Quarter 2022 Financial Results Webcast and Conference Call
02:20pm, Tuesday, 03'rd May 2022
SAN DIEGO , May 3, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2022 on May 10 at 4:30 p.m. ET / 1:30 p.m.
Halzoyme (HALO) Up 8.3% YTD: Will It Continue to Trend Higher?
02:22pm, Friday, 22'nd Apr 2022 Zacks Investment Research
Halozyme's (HALO) revenues are driven by strong demand for new partnered drugs. Restructuring initiatives are boosting margins. Robust revenue growth is expected to continue in 2022.
Halzoyme (HALO) Up 8.3% YTD: Will It Continue to Trend Higher?
12:02pm, Friday, 22'nd Apr 2022
Halozyme's (HALO) revenues are driven by strong demand for new partnered drugs. Restructuring initiatives are boosting margins.
Halozyme Open to More Acquisitions After Antares Deal
04:57pm, Tuesday, 19'th Apr 2022
After inking a deal to acquire small-cap auto-injector specialist Antares Pharma Inc. ( ATRS , Financial) for about $960 million, San Diego-based Halozyme Therapeutics Inc. ( HALO , Financial) may not
Biotech Stock Roundup: SRRA Surges on GSK Buyout, HALO Offers Update & More
05:34pm, Thursday, 14'th Apr 2022 Zacks Investment Research
Acquisition news from GlaxoSmithKline (GSK) and HALO are a few key highlights from the biotech sector during the past week.
